EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Improvement of assessment in surrogate endpoint and safety outcome of single-arm trials for anticancer drugs

Yafang Huang iD, Jinqiu Yuan

Expert Review of Clinical Pharmacology · 2024

DOI: 10.1080/17512433.2024.2344669 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Expert Review of Clinical Pharmacology, 2024. Verfasst von Yafang Huang und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of General Practice and Continuing Education, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Endpoint Determination, Neoplasms, Biomarkers. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 98 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Single-arm trials (SATs) and surrogate endpoints were adopted as pivotal evidence for accelerated approval of anticancer drugs for more than 30 years. However, concerns regarding clinical evidence quality in trials, particularly in the SATs of anticancer drugs have increasingly been raised. SAT may not always provide strong evidence due to the lack of control and endpoint of overall survival that is typically present in randomized controlled trials. AREAS COVERED: Clinical trial endpoint adjudication is a crucial factor in surrogate outcome measurement to ensure the data quality of the clinical trial of anticancer drugs. In this review, we systematically discuss the characteristics of adjudications in assessments in surrogate endpoint and safety outcome respectively, which are essential for ensuring reliable and transparent outcomes. Endpoint adjudication effectively reduces potential bias and mitigates variance that may be introduced by investigators when analyzing the medical records for the surrogate endpoints. We analyze the advantages and disadvantages of each type of adjudicator and provide a summary of the roles of adjudicators. EXPERT OPINION: By suggestion of improving data reliability and transparency in pivotal trials, this review aims to supply a strategy for better clinical investigation for anticancer drugs, ultimately leading to better patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsEndpoint DeterminationNeoplasmsBiomarkersResearch DesignRandomized Controlled Trials as TopicHumansReproducibility of ResultsData AccuracyClinical Trials as TopicDrug Approval

Stichwörter der Autor:innen

Oncological clinical trialanticancer activityendpoint adjudicationsafety outcomesingle-arm trialssurrogate endpoint

Substanzen

Antineoplastic AgentsBiomarkers

Autor:innen und Institutionen

  • School of General Practice and Continuing Education, Capital Medical University, Beijing, China.
  • Clinical Research Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China.

ORCID-Profile: Yafang Huang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Huang, Y., & Yuan, J. (2024). Improvement of assessment in surrogate endpoint and safety outcome of single-arm trials for anticancer drugs. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2024.2344669

Vancouver

Huang Y, Yuan J. Improvement of assessment in surrogate endpoint and safety outcome of single-arm trials for anticancer drugs. Expert Review of Clinical Pharmacology. 2024. doi:10.1080/17512433.2024.2344669

BibTeX
@article{Huang2024,
  author = {Huang, Yafang and Yuan, Jinqiu},
  title = {Improvement of assessment in surrogate endpoint and safety outcome of single-arm trials for anticancer drugs},
  journal = {Expert Review of Clinical Pharmacology},
  year = {2024},
  doi = {10.1080/17512433.2024.2344669}
}
Kostenlos starten →